Unlock stock picks and a broker-level newsfeed that powers Wall Street.

KOSDAQ - Delayed Quote KRW

AprilBio Co.,Ltd. (397030.KQ)

15,690.00
+290.00
+(1.88%)
As of 11:12:26 AM GMT+9. Market Open.
Loading Chart for 397030.KQ
  • Previous Close 15,400.00
  • Open 15,800.00
  • Bid 15,680.00 x --
  • Ask 15,690.00 x --
  • Day's Range 15,360.00 - 15,850.00
  • 52 Week Range 11,980.00 - 25,900.00
  • Volume 91,500
  • Avg. Volume 299,415
  • Market Cap (intraday) 343.878B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 35,000.00

AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops products based on its long-acting protein medicine platform technology. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Chuncheon-si, South Korea.

www.aprilbio.com

Recent News: 397030.KQ

View More

Performance Overview: 397030.KQ

Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

397030.KQ
3.15%
KOSPI Composite Index (^KS11)
4.83%

1-Year Return

397030.KQ
1.55%
KOSPI Composite Index (^KS11)
4.10%

3-Year Return

397030.KQ
60.92%
KOSPI Composite Index (^KS11)
7.00%

5-Year Return

397030.KQ
60.92%
KOSPI Composite Index (^KS11)
31.38%

Compare To: 397030.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 397030.KQ

View More

Valuation Measures

Annual
As of 4/22/2025
  • Market Cap

    337.52B

  • Enterprise Value

    246.15B

  • Trailing P/E

    16.87

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.26

  • Price/Book (mrq)

    3.71

  • Enterprise Value/Revenue

    8.95

  • Enterprise Value/EBITDA

    11.12

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 397030.KQ

View More

Company Insights: 397030.KQ

Research Reports: 397030.KQ

View More

People Also Watch